RT-PCR Detection Panel for Specific COVID-19 and SARS Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing assays for detecting SARS-CoV-2 virus suffer from cross-reactivity with human nucleic acid, leading to inaccurate results, and there is a need for a more precise and reliable method for universal detection of SARS-like coronaviruses and specific detection of SARS-CoV-2.
Innovation Solution
A detection panel utilizing an N2 assay for SARS-CoV-2 specificity, an E assay for universal SARS-related coronavirus detection, and an RP assay as an internal control, combined with a real-time RT-PCR method using specific primers and probes, is employed to analyze samples from various specimen types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If the N1 (nucleocapsid) detection assay is used for SARS-CoV-2 detection, then the assay provides specific detection capability, but it cross-reacts with SARS-CoV causing inaccurate results
Solution Approach 1:
The patent segments the detection strategy into three separate assays (N2 for SARS-CoV-2 specificity, E for universal SARS coronavirus detection, and RP for internal control) rather than relying on a single assay. This segmentation allows each assay to have optimized specificity while the combination provides comprehensive and accurate detection, eliminating the cross-reactivity problem of the N1 assay.
Solution Approach 2:
The patent changes the detection parameters by selecting different viral gene targets (nucleocapsid N2 region for SARS-CoV-2 specificity, envelope E region for universal detection) and optimizing primer-probe sequences. This parameter change enables differentiation between SARS-CoV-2 and SARS-CoV, resolving the cross-reactivity issue while maintaining detection sensitivity.
2Adaptability or versatility
If the N3 (nucleocapsid) detection assay is used, then the assay provides broad detection capability, but it cross-reacts with human nucleic acid leading to false results
Solution Approach 1:
The patent divides the detection system into multiple specialized assays instead of using a single broad-spectrum assay. The N2 assay targets SARS-CoV-2 specifically, the E assay provides universal SARS coronavirus detection, and the RP assay serves as an internal control for human nucleic acid detection. This segmentation eliminates cross-reactivity with human nucleic acid while maintaining broad SARS coronavirus detection capability.
Solution Approach 2:
The patent introduces the RP (human RNase P) assay as an intermediary control mechanism. This internal control assay detects human nucleic acid to monitor for contamination and ensure sample integrity, allowing the system to distinguish between true viral detections and false positives from human nucleic acid cross-reactivity.
3Ease of operation
If a single assay is used for coronavirus detection, then the detection process is simplified, but it cannot differentiate between SARS-CoV-2 and other SARS-like coronaviruses
Solution Approach 1:
The patent implements a segmented multi-assay panel where each assay targets a specific viral region with defined specificity (N2 for SARS-CoV-2, E for universal SARS coronaviruses). While the panel contains multiple assays, the standardized format and automated analysis maintain operational simplicity, achieving both differentiation capability and ease of use.
Solution Approach 2:
The patent creates a universal detection panel that can identify multiple SARS-like coronaviruses through a standardized multi-assay format. The panel simultaneously performs specific SARS-CoV-2 detection, universal SARS coronavirus detection, and internal control monitoring, providing multi-functional capability while maintaining a consistent operational workflow.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides accurate and sensitive detection of SARS-CoV-2, minimizing cross-reactivity and ensuring reliable results through the use of an internal control, enabling precise identification of the virus in clinical specimens.
Implementation Method 1
analyzing at least a first portion of the sample for one region in a SARS-CoV-2 nucleocapsid (N) gene using an N2 assay, analyzing at least a second portion of the sample for universal detection of SARS coronaviruses (E) using an E assay; and analyzing at least a third portion of the sample to detect human RNase P (RP)
Data Source
AI summary
A detection panel for the universal detection of SARS-like coronaviruses and SARS-CoV-2 viruses and a method for using the detection panel are provided. The detection panel may be known as a Center for Discovery and Innovation (“CDI”) detection panel (CDI Enhanced COVID-19 Test) and may also include an additional primer/probe set in the detection panel to detect the human RNase P gene (RP) in control samples and clinical specimens. The detection panel is designed for both universal detection of SARS-like coronaviruses using an E gene (envelope) detection assay, and specific detection of the SARS-CoV-2, using an N2 (nucleocapsid) detection assay.